Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

Eli Lilly (LLY) shares traded down more than 6% Tuesday after the company reported revenue guidance for the fourth quarter of 2024 that missed Wall Street expectations. Lilly revised its revenue ...

NEW YORK — Most U.S. stocks rose Tuesday following an encouraging update on inflation, though drops for Eli Lilly and other influential stocks kept indexes in check. The Standard & Poor’s 500 ...

Jan 13 (Reuters) - Eli Lilly (LLY.N), opens new tab said ... against Valhalla was filed in the Eastern District of New York. Lilly said Thrive has designed its website and advertising materials ...